BridgeBio Oncology Therapeutics, Inc.

BBOT · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueNot enough data yet
News flowBalanced
MomentumWeak
SafetyBalanced

Overall confidence 36/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Medium (17/100) · Gap confidence 45/100Some evidence isn't yet fully priced in.

This month at a glance

AIR Score™ change: -5Slipped -5 on softer inputs.

Cycle window9 Sep 2026 → 10 Sep 2026

Momentum-4Weighed on the latest score.

Safety-1Weighed on the latest score.

Evidence timeline

[8-K 2.02] BridgeBio Oncology Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 11, 2026 · 8-K
[8-K 5.02] BridgeBio Oncology Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Jun 16, 2026 · 8-K
[8-K 2.02] BridgeBio Oncology Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 12, 2026 · 8-K
[8-K 5.02] BridgeBio Oncology Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Apr 27, 2026 · 8-K
[8-K 5.02] BridgeBio Oncology Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Apr 20, 2026 · 8-K
[8-K 5.02] BridgeBio Oncology Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Mar 24, 2026 · 8-K
[8-K 2.02] BridgeBio Oncology Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Mar 5, 2026 · 8-K
[8-K 8.01] BridgeBio Oncology Therapeutics, Inc. — Other EventsSEC · SEC EDGAR
Jan 7, 2026 · 8-K
[8-K 2.02] BridgeBio Oncology Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Nov 12, 2025 · 8-K
[8-K 3.02] BridgeBio Oncology Therapeutics, Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGAR
Aug 11, 2025 · CURRENT REPORT
[8-K 2.01] BridgeBio Oncology Therapeutics, Inc. — Completion of Acquisition or Disposition of AssetsSEC · SEC EDGAR
Aug 11, 2025 · CURRENT REPORT
[8-K 1.01] BridgeBio Oncology Therapeutics, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Aug 11, 2025 · CURRENT REPORT

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.